Literature DB >> 2313415

Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient.

N M Katz1, P F Pierce, R A Anzeck, M S Visner, H G Canter, M L Foegh, D L Pearle, C Tracy, A Rahman.   

Abstract

Pulmonary aspergillosis developed in a 52-year-old man 2 months after heart transplantation for ischemic cardiomyopathy. Conventional amphotericin B therapy caused marked deterioration of his already compromised kidney function after only 10% of the projected total dose. Conversion to liposomal encapsulated amphotericin B was associated with reversal of the kidney dysfunction and clearing of the pulmonary infiltrate. It is now 16 months since completion of therapy, and there is no evidence of recurrent infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2313415

Source DB:  PubMed          Journal:  J Heart Transplant        ISSN: 0887-2570


  11 in total

Review 1.  Antifungal treatment strategy in leukemia patients.

Authors:  T Büchner; N Roos
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

Review 2.  Heart-lung transplantation for cystic fibrosis.

Authors:  T W Higenbottam; B Whitehead
Journal:  J R Soc Med       Date:  1991       Impact factor: 5.344

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 4.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

5.  Amphotericin B lipid complex therapy of experimental fungal infections in mice.

Authors:  J M Clark; R R Whitney; S J Olsen; R J George; M R Swerdel; L Kunselman; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

6.  Cavitating pulmonary cryptococcosis developing in an HIV antibody patient despite prior treatment with fluconazole.

Authors:  R J Coker; D Bell; B S Peters; S M Murphy
Journal:  Genitourin Med       Date:  1992-02

Review 7.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

8.  Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer.

Authors:  W Emminger; W Graninger; W Emminger-Schmidmeier; A Zoubek; K Pillwein; M Susani; A Wasserer; H Gadner
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

9.  Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B.

Authors:  E Anaissie; V Paetznick; R Proffitt; J Adler-Moore; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-08       Impact factor: 3.267

Review 10.  Optimizing efficacy of amphotericin B through nanomodification.

Authors:  Suresh P Vyas; Swati Gupta
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.